User noticed beard and sideburn hair loss, and thinning eyebrows, diagnosed with alopecia barbae and male pattern baldness, and prescribed Desonide cream. User seeks feedback on Desonide cream.
RU58841 is discussed for hair loss treatment, with mixed reviews on its effectiveness and side effects. Users mention using it in an ethanol/PG solution and combining it with other treatments like dutasteride.
The user has been using finasteride for 7 months and is experiencing some regrowth but struggles with an oily scalp despite trying ketoconazole and salicylic acid. They are seeking advice on managing the oily scalp and are reassured by others that regrowth is visible.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.
A user is 8 months into treating hair loss with finasteride, minoxidil, ketoconazole, and pyrilutamide, but feels their condition is worsening. They are considering increasing their finasteride dosage due to aggressive hair loss and are experiencing scalp itchiness.
The conversation discusses using Rogaine (Minoxidil) and ketoconazole for hair regrowth, with interest in trying a formulation with Azelaic Acid for potentially better results. Concerns about Azelaic Acid's effectiveness and safety, including skin sensitivity to sunburn, are mentioned.
Mixing Nizoral and T-Gel in a 1:1 ratio and using it three times a week provided relief from persistent seborrheic dermatitis. This treatment is recommended for those with stubborn SD.
A user experienced a dry, scaly scalp two weeks after microneedling with a dermapen at 1mm and applying Rogaine foam. They tried moisturizers and coconut oil without success and are seeking advice.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.
RU58841 powder is discussed for hair loss treatment, with suggestions to use a 5% solution in isopropyl alcohol. One user mentions using RU injections directly to the scalp.
The conversation discusses hair loss treatments, focusing on reducing scalp itching and dandruff using natural shampoos, witch hazel, and apple cider vinegar. The user also mentions using finasteride and observing potential regrowth, though it's difficult to confirm.
The conversation is about someone's three-year experience with irregular derma rolling, Minoxidil, and Redensyl for hair loss, hoping to thicken areas with fine hair.
The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.
1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
Topical minoxidil with retinoic acid is effective but causes scalp irritation, leading the user to consider switching to 2.5mg oral minoxidil. Oral minoxidil may cause body hair growth and heart-related side effects, so it's advised to use it under medical guidance.
A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Hair growth success may be linked to addressing scalp fungi issues, with treatments like minoxidil, finasteride, and dutasteride being important. DHT may contribute to scalp microbial issues, potentially causing inflammation and hair loss.
A 15-year-old experiencing severe diffuse thinning plans to use minoxidil, dermarolling, and possibly ketoconazole, with hopes to later incorporate finasteride. Concerns about starting finasteride too young and the need for a dermatologist consultation are discussed.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.